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Abstract:  Regular  exercise,  particularly  progressive  resistance  training  (PRT),  is 
recognized  as  one  of  the  most  effective  strategies  to  prevent  age-related  muscle  loss 
(sarcopenia),  but  its  effects  on  muscle  function  are  mixed.  However,  emerging  data 
indicates that high velocity PRT (fast concentric muscle contractions) is more effective for 
improving  functional  outcomes  than  traditional  PRT.  In  terms  of  falls  prevention,  
high-challenging  balance  training  programs  appear  to  be  most  effective.  There  is  also 
compelling evidence that supplemental vitamin D is an effective therapeutic option for 
falls  prevention.  The  findings  from  a  recent  meta-analysis  revealed  that  supplemental 
vitamin D at a dose of at least 700–1,000 IU/d or an achieved serum 25(OH)D level of at 
least 60 nmol/L was associated with reduced falls risk among older individuals. Based on 
these findings, it is possible that the combination of exercise and vitamin D could have a 
synergistic effect on muscle morphology and function, particularly since both interventions 
have been shown to have beneficial effects on type II  “fast twitch” muscle fibers and 
systemic  inflammation,  which  have  both  been  linked  to  losses  in  muscle  mass  and 
function. Unfortunately however, the findings from the limited number of factorial 2 ×  2 
design RCTs indicate that additional vitamin D does not enhance the effects of exercise on 
measures of muscle morphology, function or falls risk. However, none of these trials were 
adequately powered to detect a “synergistic” effect between the two treatment strategies, 
but it is likely that if an exercise-by-vitamin D interaction does exist, it may be limited to 
situations when vitamin D deficiency/insufficiency is corrected. Further targeted research 
in “high risk” groups is still needed to address this question, and evaluate whether there is 
a threshold level of serum 25(OH)D to maximize the effects of exercise on muscle and 
falls risk.  
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1. Introduction 
One of the most striking consequences of ageing is the involuntary loss in muscle mass, a condition 
termed sarcopenia. Sarcopenia contributes to a decrease in muscle strength (force producing capacity 
of muscle), loss of muscle power (ability to produce force rapidly), and reduced muscular endurance 
(muscle fatigue) [1]. The clinical relevance of these changes to both health and functional capacity is 
highlighted by the increasing evidence that they have been associated with a number of metabolic, 
cardiovascular  and  musculoskeletal  related  disorders,  particularly  the  decline  in  functional 
performance  which  has  been  linked  to  an  increased  risk  of  falls  and  disability,  and  a  loss  of 
independence and even increased mortality in the elderly [1]. Thus, identifying interventions that can 
prevent muscle loss and enhance muscle function to reduce the risk of falls is crucial to ensure that 
older adults can live independently and relatively disease and disability free into old age. 
2. Age-Related Changes in Muscle 
In both men and women the age-related loss in muscle mass begins around the fourth decade of life 
(~30 years of age), with the greatest losses occurring after the age of 50 [1,2]. While there is marked 
inter-individual  variability  in  this  loss  due  to  differences  in  genetic,  lifestyle  and  disease-related 
factors, it has been reported that as much as 40% of muscle mass (or size) is lost from around the age 
of 20 up to 60 to 90 years [1,2]. Men tend to experience a greater loss than women [3], which may be 
related to gender differences in hormonal factors. In addition, there is a preferential loss in muscle 
mass in the lower extremities [2], which has been attributed in part to the age-related reduction in 
physical activity. Muscle strength also peaks around the age of 30 but is maintained until about the age 
of 45 to 50 years [4-6]. Thereafter, the rate of decline in men and women is approximately 12 to 15% 
per decade [1,7], with even greater losses (up to 30% over 12 years) reported in some longitudinal 
studies [8] and the very old [9]. This reduction in muscle mass or size with ageing is due to similar 
losses in the number of type I (slow twitch) and type II (fast twitch) muscle fibres, but there is a 
selective reduction in the size of type II muscle fibres [10]. This atrophy of type II muscle is important 
because it may account for the accelerated loss in muscle power with ageing. For instance, it has been 
shown that muscle power or the ability to produce force rapidly declines earlier and more rapidly with 
age than muscle strength or endurance [6]. The clinical relevance of this loss in muscle power has been 
demonstrated in a number of studies which have reported that relative to muscle strength, the deficits 
in muscle power have a greater effect on functional performance [11,12]. Most activities of daily 
living for older adults and the elderly, such as walking, rising from a chair and climbing stairs, require 
power and not strength alone. Since reduced muscle power has been shown to be a strong predictor of 
disability [12] and falls [13] in the elderly, targeting deficits in lower extremity muscle power are 
likely to represent an ideal and effective strategy to reduce the risk of falls and related injuries in 
older adults.  Nutrients 2010, 2  
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3. Factors Contributing to Sarcopenia 
While the mechanisms responsible for the age-associated changes in muscle remain to be fully 
determined,  multiple  interrelated  factors  have  been  implicated.  Decreased  physical  activity,  poor 
nutrition  and  neurological  changes  have  all  been  identified  as  important  contributing  factors  [1].  
Age-related reductions in serum concentrations of sex steroids, growth factors [IGF-1] and circulating 
25-hydroxyvitamin D [25(OH)D] have also been implicated [1], all of which may be exacerbated by 
reduced levels of physical activity and inadequate nutrition. There are also indications that chronic  
low-grade inflammation that accompanies ageing, as reflected by increased levels of TNF-α, IL-6 and 
CRP [14,15] can exert a catabolic effect on muscle tissue [16]. Indeed, recent studies have reported 
that elevated levels of various inflammatory cytokines have been associated with sarcopenia [17], poor 
physical performance [18], accelerated losses in muscle strength and lean mass [17] and increased 
disability [19]. More specific details regarding the potential underlying mechanisms that contribute to 
the age-related changes in muscle can be found in several reviews [1,4]. It is clear however, that 
modifiable lifestyle factors can play an important role in preventing sarcopenia. In particular, regular 
exercise,  particularly  progressive  resistance  training,  and  adequate  nutrition  (energy,  protein  and 
vitamin D) alone or in combination are recognized as key factors that can help to prevent muscle loss 
and optimize muscle function to reduce the risk of falls and fractures in the elderly.  
4. Exercise, Muscle Health and Function in the Elderly 
There is a large body of evidence from RCTs showing that progressive resistance training (PRT) 
can produce large increases in muscle strength (100% or more), and improve or maintain muscle mass 
and cross-sectional area in both older men and women [20-22] and even the elderly [23]. Importantly, 
the current evidence also indicates that there is a dose-response effect of training on muscle strength, 
with  high  intensity  PRT (60–80%  of maximum strength) being more effective than low-moderate 
intensity programs [20]. While it seems intuitive that these improvements would also enhance muscle 
function, these types of programs have not been shown to consistently improve measures of functional 
performance,  including  balance,  gait  or  postural  sway.  Indeed,  several  systematic  reviews  have 
reported that conventional PRT programs have no effect on measures relating to activities of daily 
living  and  only  a  small  to  moderate  effect  on  functional  ability,  despite  large  gains  in  muscle  
strength [24,25]. This is perhaps not surprising when considering the concept of training specificity; 
most  traditional  PRT  programs  encourage  slow  velocity  muscle  contractions  [2–4  sec  for  the 
concentric (lifting) phase] at a moderate to high percentage of maximal force (~60–80% maximal 
strength).  However, many  common tasks  related  to  mobility and  daily  perturbations  require rapid 
coordinated and dynamic contractions within 50 to 200 ms, which is considerably less than the time 
needed to  achieve  maximal  muscle  force  (~400–600 ms) [26]. Therefore, strategies which aim to 
enhance the ability to generate force quickly (muscle power), and which are specific to tasks of daily 
living are likely to be more relevant to the maintenance of physical function in older persons. 
In recent years there has been growing interest in the role of high velocity-PRT (or power training) 
as a novel form of training to enhance muscle power and function in older adults. This mode of 
training is characterized by rapid concentric movements followed by a slower eccentric (lowering) 
phase performed at moderate to high loads. As highlighted in a recent meta-analysis, the findings from Nutrients 2010, 2  
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several RCTs conducted over 8 to 24 weeks indicate that high velocity PRT is effective for improving 
muscle strength, muscle power and function in healthy older adults [20]. Perhaps more importantly, 
this same meta-analysis reported that high velocity PRT training was more effective for improving 
measures of muscle function (chair rising time, stair climbing, walking speed) in older adults than 
traditional PRT, despite similar gains in maximal muscle strength [20]. The mechanism underlying 
these greater gains in function have been attributed to the fact that high velocity-PRT can improve 
motor-unit firing rate, synchronization, and levels of activation resulting in an increase in the number 
and size of type II fast twitch fibres, and thus more rapid and forceful muscle contractions which are 
important for dynamic functional tasks [27].  
To our knowledge, no studies have examined whether high velocity PRT can prevent falls, but there 
is considerable evidence to support the role of exercise as an effective falls prevention strategy. For 
instance, the findings from a recent systemic review with meta-analysis of RCTs that compared fall 
rates  in  older  people  who  undertook  exercise  programs  compared  to  those  that  did  not  exercise 
revealed that exercise reduced the rate of falling by 17% [44 trials with 9,603 participants, rate ratio 
(RR) = 0.83 (95% CI, 0.75–0.91)] [28]. Furthermore, the authors reported that the greatest relative 
effects of exercise on fall rates were observed in those programs that incorporated high challenge 
balance exercises and a total dose of training >50 hours over the trial period (e.g., twice weekly over 
25 weeks). Interestingly, moderate to high intensity PRT did not reduce the rate of falling and trials 
that included walking as part of the exercise program were associated with an increased falls risk  
[RR 1.32 (95% CI, 1.11, 1.58)] [28].  
In summary, the current evidence indicates that to prevent or slow the age-related decline in muscle 
mass and strength, moderate to high intensity PRT should be prescribed. To help offset the decline in 
muscle function, high velocity PRT and targeted muscle balance and functional training appear to be 
most effective. For falls prevention, the available evidence indicates that older adults should undertake 
moderate to high challenging balance activities. However, with all training programs there is typically 
marked inter-individual variability in the response to training. For instance, Hubal et al. [29] reported 
that  changes  in  muscle  size  and  strength  ranged  from  −2  to  59%  and  0  to  250%,  respectively, 
following 12 weeks of PRT. While there are likely to be many factors contributing to this variability, 
differences in nutritional status are likely to play an important role. Inadequate energy and protein 
intakes  are  recognized  as  two  important  factors  that  may  blunt  the  skeletal  muscle  responses  to 
training, but low serum 25-hydroyxvitamin D levels also appear to be important. The following section 
will briefly review the current evidence relating to the role of vitamin D on muscle function and 
falls risk.  
5. Vitamin D, Muscle Function and Falls Risk 
Proximal muscle weakness has long been recognized as a predominant feature of clinical vitamin D 
deficiency [30]. However, with the discovery of vitamin D receptors (VDR) in muscle tissue, and the 
finding  that  their  numbers  decrease  with  age  [31],  there  has  been  considerable  interest  into  the 
potential therapeutic effects of vitamin D. The findings from multiple large-scale observational and 
prospective studies involving both men and women have shown that low serum 25(OH)D levels are 
related to accelerated losses in muscle mass and reduced muscular strength, reduced muscle power and Nutrients 2010, 2  
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gait speed, impaired balance and increased postural sway [31-33]. In addition, there appears to be a 
dose-response relationship between circulating 25(OH)D and muscle function. Data from The Third 
National Health and Nutrition Examination Survey (NHANES III) involving 4,100 ambulatory adults 
aged 60 years and older showed that measures of muscle  function (8-foot walk test and repeated  
sit-to-stand tests) were markedly reduced in those with the lowest 25(OH)D levels (20 nmol/L), but 
that  muscle  performance  tended  to  improve  continually  within  the  reference  range  of  22.5  to 
95 nmol/L, with the most dramatic improvements occurring in the range of 22.5 to 40 nmol/L [31]. 
This association between low vitamin D and reduced muscle function has been attributed, in part, to 
the finding that vitamin D deficiency is associated with a selective loss and atrophy of type II muscle 
fibres [34], which are the fast contracting and strong muscle fibres used to avoid falling.  
Over the past decade, there have been an increasing number of clinical trials which have shown 
that  supplementation  with  vitamin  D  (or  combined  calcium  and  vitamin  D)  can  significantly 
improve lower extremity muscle performance and reduce the risk of falling in the elderly (refer to  
Bischoff-Ferrari  et al.  [35] for an overview of high-quality trials). However, as highlighted in an 
earlier  systematic  review  not  all  studies  have  observed  a  significant  anti-fall  or  muscle  effect  of 
vitamin D supplementation [36]. This was largely ascribed to the use of low dose supplementation in 
some  of  these  trials.  In  a  5-month  multi-dose  (200,  400, 600 or  800 IU/d), double-blind RCT in 
124 nursing home residence, Broe et al. [37] reported that higher dose vitamin D supplementation 
(800 IU/d) reduced the rate of falling by 72% compared to those taking placebo or a lower dose. These 
findings  are  consistent  with  the  results  of  a  recent  meta-analysis  that  included  eight  high  quality 
double-blind RCTs (n = 2,426) ranging in duration from 2 months to 3 years in older individuals 
(mean age 65 years or older) [35]. The key findings from this study were that there was heterogeneity 
among trials for both the dose of vitamin D (<700 IU/d vs. 700–1,000 IU/d, p = 0.02) and achieved 
serum 25(OH)D level (<60 nmol/L versus 60 nmol/L, p = 0.005) (Figure 1). At a supplemental dose 
of 700–1000 IU/d, the pooled relative risk for preventing a fall was 0.81 (95% CI, 0.71–0.92), which 
represents  a  19%  risk  reduction.  There  was  no  anti-fall  effect  for  low  dose  supplementation 
(<700 IU/d,  pooled  RR 1.10 (95% CI, 0.89, 1.35).  For  an  achieved circulating 25(OH)D level of 
≥60 nmol/L, there was a 23% fall reduction [pooled RR 0.77 (95% CI, 0.65, 0.90)], but no effect at 
concentrations <60 nmol/L [pooled RR 1.35 (95% CI, 0.98, 1.84)]. Primary subgroup analysis also 
revealed that: (1) there were no significant differences in falls risk with trials that used vitamin D2 
versus vitamin D3 (12% versus 26%, p = 0.28); (2) combined calcium plus vitamin D supplementation 
was not associated with a greater risk reduction; (3) there was no gender effect; (4) the benefits were 
present in both ambulatory and institutionalized older individuals; and (5) treatment duration did not 
significantly modulate the effect of vitamin D (38% fall reduction with treatment <12 months versus 
17% with a duration 12 months).  
The beneficial effects of vitamin D on falls prevention have been largely attributed to the direct 
effect of vitamin D on muscle modulated by specific vitamin D receptors
 in human muscle tissue. In 
two  prospective  studies  of  elderly  women,  treatment  with  vitamin  D  (ergocalciferol)  or  
1-hydroxyvitamin D for 3 to 6 months was shown to increase the relative proportion and size of type II 
“fast  twitch”  muscle  fibres  [34,38].  However,  vitamin  D  has  also  been  shown  to  have  
anti-inflammatory properties, which may also explain its effects on muscle. Vitamin D deficiency has 
been associated with increased inflammation, and there is evidence that supplementation can suppress Nutrients 2010, 2  
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the release of CRP, TNF-α and IL-6 [39,40], and up-regulate the synthesis of the anti-inflammatory 
cytokine  IL-10  [41].  Recent  data  also  suggests  that  the  effects  of  vitamin  D  on  muscle  may  be 
mediated  indirectly  by  lowering  parathyroid  hormone  (PTH)  [42].  High  PTH  levels  in  older 
community dwelling adults have been reported to be associated with increased losses in grip strength 
and appendicular skeletal muscle mass over 3-years [33]. In a prospective study of 637 ambulatory men 
and  women  living  in  institutional  aged  care  facilities  followed  for  a  mean  of  10.2  months,  
Sambrook et al. [42] reported that baseline serum PTH levels were a significant predictor of time to 
first  fall,  independent  of  serum  25(OH)D.  Further  studies  are  still  needed  to  gain  a  greater 
understanding  of  the  underlying  mechanism  for  the  association  between  PTH,  muscle  and  falls. 
However, it is possible that the influence of PTH on falls may be related to its effect on inflammation 
as elevated PTH levels have been associated with increased production of IL-6 [43], which has been 
shown to inhibit the production of insulin-like growth factor-1 (IGF-1) and is also related to lower 
muscle mass and strength [44]. There is also some evidence that PTH may have a direct effect of skeletal 
muscle.  For  instance,  primary  hyperparathyroidism  has  been  associated  with  muscle  weakness  that 
improves following parathyroidectomy [45]. 
Figure 1. Fall prevention by dose and achieved 25(OH)D concentrations. Circles represent 
relative risks and error bars represent 95% confidence intervals. Trendline is based on 
series of effect sizes (circles). There were three trials with 800 IU D3 
w5 w6 w7, so the effect 
size for 800 IU D3 is the pooled result from these three trials. Likewise, the effect size for 
1,000 IU D2 is the pooled result from the two trials with 1,000 IU D2 
w3 w4. We have listed 
the same dose D2 and D3 separately in the graph to account for their potential different 
impact on fall reduction. As there were two data points from the Broe et al. [37] trial that 
reached 48 nmol/L 
w1, two trials that reached 60 nmol/L 
w1 w3 and two trials that reached 
66 nmol/L 
w6 w7, we pooled each of the sets. On the basis of visual inspection of Figure 1, 
the benefits of vitamin D for fall risk started at a dose of 700 IU a day. Reproduced from 
Bischoff-Ferrari et al. [35], with permission from BMJ Publishing Group Ltd. 
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Figure 1. Cont. 
 
In  the  elderly,  there  is  some  evidence  that  the  increased  rate  of  falling  and  decreased  muscle 
strength and function may be related to the age-related decline in kidney function and the associated 
decrease in the production of the active form of vitamin D, 1,25-dihydroxyvitamin D [46-48]. Because 
active forms of vitamin D do not need hydroxylation in the kidney, it is hypothesized that their effects 
of falls should be less affected by changes in kidney function with advancing age [35]. Several RCTs 
have shown that treatment with 1α-hydroxyvitamin D3 or 1,25-dihydroxyvitamin D3 for 9 to 36 months 
can reduce the risk of falls by 16 to 24% [49,50]. While these benefits are similar to those observed 
with supplemental vitamin D, it is important to note that participants treated with the active forms of 
vitamin D were more likely to have hypercalcaemia (up to 3mmol/L) compared to the controls [35].  
In  summary,  the  available  evidence  from  RCTs  and  meta-analyses  indicate  that  supplemental 
vitamin D at a dose of at least 700–1,000 IU per day and achieving a serum 25(OH)D level of 60 to 
95 nmol/L appears optimal to improve muscle function and prevent falls in the elderly. However, it is 
important to recognize that the dose of vitamin D required to achieve a serum 25(OH)D level of 
around 60 to 75 nmol/L will vary among individuals largely based on their initial 25(OH)D levels, 
BMI, level of sun exposure and race-ethnicity. Long-term compliance with daily supplementation is 
also a common problem for the elderly, but whether high dose supplementation is the answer remains 
to be determined in light of the recent findings from a double-blind, placebo controlled trial which 
found that a single annual dose of 500,000 IU administered orally to older women was associated with 
a significant increased risk of falls and fractures [51]. 
6. Interaction between Vitamin D and Exercise on Muscle in the Elderly 
Since both vitamin D supplementation and PRT have been shown to independently have beneficial 
effects  on  muscle  morphology  and  function  in  the  elderly,  in  addition  to  markers  of  systemic 
inflammation which may mediate the effects, combining these two factors may represent the ideal 
approach to optimize muscle function and reduce the risk of falls. However, few studies have been 
appropriately designed to test whether additional vitamin D [or increased serum 25(OH)D] enhances Nutrients 2010, 2  
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the muscle or functional responses to exercise. More specifically, if there is a “synergistic interaction” 
between these two strategies. The term “interaction” describes the combined effects of two or more 
variables as being more than the sum of their individual effects. That is, an “interaction” effect implies 
a result which is more than simply “additive”; it is multiplicative. To test this hypothesis a factorial 2 ×  2 
design  RCT  with  four  groups  and  an  adequate  sample  size  is  required:  exercise  and  no-exercise 
combined with vitamin D and placebo.  
In one of the few factorial trials to have examined the potential interaction between exercise and 
vitamin  D,  Bunout  et  al.  [52]  reported  that  biweekly  (~1.5  hours)  strength,  balance  and  aerobic 
training plus vitamin D and calcium supplementation (400 IU/d and 800 mg/d) for 9 months did not 
enhance muscle mass or function compared to either exercise or vitamin D alone in 96 elderly subjects 
aged 70 years with 25(OH)D <40 nmol/L. However, training significantly improved measures of 
muscle strength and function [timed-up-and-go (TUG)], and participants supplemented with vitamin D 
had greater gait speed at follow-up. The lack of an interactive effect in this trial can be attributed to a 
number of factors, including the small sample size, poor exercise compliance (mean 53%), the low 
volume and intensity of training, and the low vitamin D dose (400 IU/d) and subsequent moderate 
increase in serum 25(OH)D levels (31 to 66 nmol/L).  
In an 18-month factorial design RCT in 180 healthy community-dwelling men aged 50–79 years 
(mean 61 years), we recently reported that daily consumption of low-fat fortified milk providing an 
additional  800  IU  vitamin  D3,  1,000  mg  calcium,  13.2  g  protein  and  836  kJ  of  energy  did  not 
significantly enhance the effects of PRT on lower extremity muscle size, strength or function [53]. 
Although the gains in mid-thigh muscle cross-sectional were two- to three-fold greater in the exercise 
plus  fortified  milk  group  compared  with  either  of  these  groups  alone  or  the  control  group,  the 
“synergistic”  interaction  term  was  not  significant.  This  was  most  likely  due  to  the  fact  that  the 
participants in our study were healthy community-dwelling men with adequate energy and protein 
intakes, and sufficient circulating 25(OH)D levels (>75 nmol/L) [53]. Based on these findings, it is 
likely that if an exercise-by-vitamin D (nutrition) interaction does exist, it may be limited to situations 
when vitamin D deficiency/insufficiency is corrected. 
A recent 12-month factorial design RCT in 173 patients aged 65 years and older (mean 84 years) 
with acute hip fracture and vitamin D deficiency [mean 25(OH)D ~30 nmol/L] examined the combined 
effects of exercise and supplemental vitamin D on rate of falls [54]. In this study, participant were 
randomized to an extended physiotherapy (PT) exercise program (supervised 60 min/d during acute 
care plus an unsupervised home program) or standard PT (supervised 30 min/d during acute care with 
no home training), with either 2,000 or 800 IU/d of cholecalciferol (double-blinded). The primary 
outcome was the rate of falls, and the secondary outcome was hospital readmissions. There was no 
interaction between the two treatment regimens, but the authors did hypothesize a priori that there 
would be an additive and not a synergistic benefit. Subsequent main effects analysis revealed that the 
extended PT reduced the rate of falls by 25%, with even greater benefits observed in terms of both 
falls prevention and muscle function in those who participated in the home program at least once a 
week.  Treatment  with  2,000  IU/d  compared  to  800  IU/d  of  vitamin  D  did  not  lead  to  a  greater 
reduction in falls, which may be explained by the finding that 25(OH)D levels increased from around 
30  nmol/L  to  greater  than  75–80  nmol/L  in  both  groups  after  12  months  (800  IU/d,  88  nmol/L; 
2,000 IU/d,  112  nmol/L).  Interestingly however,  treatment with  2,000 IU/d  of vitamin  D (but not Nutrients 2010, 2  
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extended PT) led to a 39% reduction in the rate of hospital readmissions compared to 800 IU/d. Based 
on these findings, the authors concluded that these two strategies may provide  an ideal treatment 
approach because they address two different but common complications after hip fracture.  
While  it  is  clear  that  further  adequately  powered,  factorial  design  RCTs  are  needed,  another 
important question that should be examined is whether vitamin D status can predict changes in muscle 
morphology or function following training. In a longitudinal study of 80 Japanese community dwelling 
frail elderly people, Okuno et al. [55] reported that the greatest improvements in various measures of 
functional performance (alternate step, TUG, functional reach and 5-m walk) following 3-months of 
training [45 min of supervised balance and mobility exercise and daily home-based exercise (walking)] 
occurred in those with serum 25(OH)D levels greater than 67.5 nmol/L (highest quartile). Participants 
with  serum  25(OH)D  levels  below  47.5  nmol/L  did  not  exhibit  any  significant  improvements  in 
function.  These  findings  provide  preliminary  data  indicating  that low serum 25(OH)D levels may 
attenuate the potential exercise-induced gains in muscle function following training. However, further 
research  is  needed  to  resolve  whether  there  is  a  threshold  levels  to  maximize  muscle  health  and 
functional responses to exercise.  
7. Conclusions 
Regular  exercise,  particularly  progressive  resistance  training,  high-velocity  power  training  and 
moderate-  to  high-challenging  balance  exercises,  and  adequate  supplementation  with  vitamin  D  
(at  least  700–1,000  IU/d  or  a  dose  required  to  maintain  serum  25(OH)D  levels  between  60  and 
95 nmol/L), have been independently shown to be important for maintaining or optimizing muscle 
morphology, strength and power, and muscle function in older adults and the elderly. In addition, both 
interventions have been shown to have beneficial effects on type II muscle fibers, which are the fast 
contracting  and  strong  muscle  fibres  used  to  avoid  falling,  as  well  as  markers  of  systemic 
inflammation, which have been linked to sarcopenia and its detrimental correlates such as reduced 
muscle function, decreased muscle power, and increased disability. Therefore, combining these two 
modifiable lifestyle factors may represent an ideal approach to reduce the risk of falls and related 
injuries in the elderly. Unfortunately however, the findings from the limited number of factorial 2 ×  2 
design RCTs which have addressed this question indicate that additional vitamin D does not enhance 
the effects of exercise on measures of muscle morphology, function or falls risk. However, none of 
these  trials  were  adequately  powered  to  detect  a  “synergistic”  effect  between  the  two  treatment 
strategies. Therefore, further targeted research in “high risk” groups is still needed to resolve whether 
supplemental vitamin D in combination with exercise can enhance muscle function, and if so, whether 
there is  a  threshold  level of serum 25(OH)D to maximize the effects of exercise on both muscle 
performance and falls risk.  
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